Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Infect Dis. 2002 Oct 1;35(7):866-72. Epub 2002 Sep 10.

Ganciclovir-resistant cytomegalovirus in organ transplant recipients.

Author information

  • 1Department of Laboratory Medicine, University of Washington Medical Center, Seattle, WA 98195-7110 , USA. limaye@u.washington.edu

Abstract

Ganciclovir-resistant (GanR) cytomegalovirus (CMV) is an emerging clinical problem in organ transplant recipients, particularly recipients of kidney and pancreas and lung transplants. GanR CMV, a late posttransplantation complication, is observed predominantly among CMV-seronegative recipients of organs from seropositive donors, especially among recipients receiving intensive immunosuppression and having prolonged exposure to ganciclovir. Given the limitations of current diagnostic methods, if GanR CMV is clinically suspected, empirical treatment with intravenously administered foscarnet should be used in conjunction with reductions in immunosuppressive therapy and possibly CMV hyperimmune globulin. Better diagnostic tools and newer, less-toxic antiviral agents with different mechanisms of action are urgently needed to decrease the morbidity associated with this complication in organ transplant recipients.

PMID:
12228824
DOI:
10.1086/342385
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center